

Janet Baack Kukreja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7650510/publications.pdf>

Version: 2024-02-01

24
papers

238
citations

1040056

9
h-index

996975

15
g-index

24
all docs

24
docs citations

24
times ranked

390
citing authors

#	ARTICLE	IF	CITATIONS
1	Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 9.e19-9.e27.	1.6	5
2	Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 237.e1-237.e5.	1.6	6
3	Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. <i>European Urology Focus</i> , 2021, 7, 71-77.	3.1	3
4	Bladder cancer biomarkers: Past and future directions. <i>BJUI Compass</i> , 2021, 2, 7-8.	1.3	2
5	Oncologic Equipoise Between Robotic and Open Radical Cystectomy. <i>Journal of Endourology</i> , 2021, 35, 1168-1176.	2.1	1
6	Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. <i>European Urology Focus</i> , 2020, 6, 88-94.	3.1	25
7	Enhanced recovery after surgery review and urology applications in 2020. <i>BJUI Compass</i> , 2020, 1, 5-14.	1.3	6
8	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 2691-2698.	2.2	10
9	Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging. <i>European Urology Oncology</i> , 2019, 2, 257-264.	5.4	5
10	Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: A prospective randomized clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 181.e7-181.e14.	1.6	10
11	Organizing a clinical trial for the new investigator. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 336-339.	1.6	6
12	Perioperative venous thromboembolism in urologic oncology procedures, risk factors, and prevention. <i>Current Opinion in Urology</i> , 2018, 28, 227-232.	1.8	1
13	Secondary Tumors After Urinary Diversion. <i>Urologic Clinics of North America</i> , 2018, 45, 91-99.	1.8	4
14	Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2018, 4, 720-724.	3.1	23
15	Antibiogram Directed Prophylaxis for Transrectal Prostate Biopsy: An Application of Recommendations in the Setting of High Fluoroquinolone Escherichia coli Resistance. <i>Urology Practice</i> , 2017, 4, 486-492.	0.5	0
16	Quality Improvement in Cystectomy Care with Enhanced Recovery (<sc>QUICCER</sc>) study. <i>BJU International</i> , 2017, 119, 38-49.	2.5	45
17	Advances in surgical management of muscle invasive bladder cancer. <i>Indian Journal of Urology</i> , 2017, 33, 106.	0.6	10
18	Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. <i>Investigative and Clinical Urology</i> , 2016, 57, S155.	2.0	4

#	ARTICLE	IF	CITATIONS
19	The Future of Enhanced Recovery for Radical Cystectomy: Current Evidence, Barriers to Adoption, and the Next Steps. <i>Urology</i> , 2016, 96, 62-68.	1.0	21
20	Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 120.e17-120.e21.	1.6	32
21	Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 393-393.	1.6	1
22	Editorial Comment. <i>Urology</i> , 2015, 86, 972-973.	1.0	0
23	Measuring success after radical cystectomy: Feasibility of a novel composite endpoint ("poor) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	10
24	Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer. <i>BJU International</i> , 2014, 114, 844-851.	2.5	8